Home » Stocks » Xencor

Xencor, Inc. (XNCR)

Stock Price: $31.83 USD 1.74 (5.78%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $32.00 +0.17 (0.53%) Aug 3, 5:30 PM

Stock Price Chart

Key Info

Market Cap 1.81B
Revenue (ttm) 77.15M
Net Income (ttm) -61.24M
Shares Out 57.00M
EPS (ttm) -1.08
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 3, 2020
Last Price $31.83
Previous Close $30.09
Change ($) 1.74
Change (%) 5.78%
Day's Open 30.32
Day's Range 30.19 - 31.98
Day's Volume 357,979
52-Week Range 19.35 - 46.33

More Stats

Market Cap 1.81B
Enterprise Value 1.25B
Earnings Date (est) Aug 4, 2020
Ex-Dividend Date n/a
Shares Outstanding 57.00M
Float 51.88M
EPS (basic) -1.07
EPS (diluted) -1.08
FCF / Share 1.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 4.60%
Payout Ratio n/a
Shares Short 3.84M
Short Ratio 8.33
Short % of Float 16.36%
Beta 1.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 21.72
PS Ratio 23.52
PB Ratio 2.89
Revenue 77.15M
Operating Income -73.20M
Net Income -61.24M
Free Cash Flow 83.55M
Net Cash 563.73M
Net Cash / Share 9.89
Gross Margin 49.40%
Operating Margin -94.88%
Profit Margin -79.40%
FCF Margin 108.30%
ROA -6.69%
ROE -10.19%
ROIC -11.10%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (11)

Buy 9
Overweight 0
Hold 1
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

$45.70*
(43.58% upside)
Low
28.0
Current: $31.83
High
56.0
Target: 45.70
*Average 12-month price target from 10 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue15740.6046.1510927.769.5210.179.526.85
Revenue Growth285.93%-12.02%-57.67%292.7%191.62%-6.41%6.8%39.06%-
Gross Profit15740.6046.1510927.769.5210.179.526.85
Operating Income13.82-79.37-43.1244.04-18.34-16.46-10.52-6.23-9.45
Net Income26.88-70.41-38.4945.13-17.59-16.42-60.26-8.59-11.20
Shares Outstanding56.5353.9446.8241.2739.0231.392.470.070.07
Earnings Per Share0.46-1.31-0.821.07-0.45-0.52-3.85-118.86-154.95
Operating Cash Flow64.37-79.76-33.6095.2426.67-21.35-5.45-11.05-1.09
Capital Expenditures-7.35-7.20-5.31-1.51-1.92-0.78-0.120.060.08
Free Cash Flow57.02-86.96-38.9193.7324.75-22.13-5.57-11.00-1.01
Cash & Equivalents53029422413096.4354.6577.982.310.00
Total Debt10.73-----0.0120.94-
Net Cash / Debt51929422413096.4354.6577.97-18.630.00
Assets67057739042920767.8287.3211.66-
Liabilities77.0555.0573.7411544.488.5313.7831.16-
Book Value59352231631416259.2973.53-166-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Xencor, Inc.
Country United States
Employees 166
CEO Bassil I. Dahiyat

Stock Information

Ticker Symbol XNCR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: XNCR
IPO Date December 3, 2013

Description

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.